| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Purity: ≥98%
Chlorpheniramine Maleate (Piriton; Chlortrimeton; Deconamine; Neorestamin; NCIC-55265; NCIC55265; Chlo-Amine; Chlor-100; Chlor-Trimeton), the Maleate salt of Chlorpheniramine, is a potent and 1st-generation alkylamine-based histamine H1 receptor antagonist with anti-allergic effects. It suppresses the histamine H1 receptor with an IC50 of 12 nM. Chlorpheniramine has been extensively employed in the management and avoidance of allergic reaction symptoms, including urticaria and rhinitis.
| Targets |
H1 Receptor ( IC50 = 12 nM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Enzyme Assay |
Segments of isolated ileum, measuring 1 centimeter, are suspended in an organ bath that contains Tyrode solution at 32 degrees Celsius (ventilation). Using an isotonic transducer, the contractile reactions to histamine (0.54 μM) are measured. Five minutes prior to the addition of histamine, an organ bath is filled with a predetermined concentration of chlorpheniramine. The probit method is used to determine the IC50 value of chlorpheniramine.
|
||
| Cell Assay |
For 48 hours, cells are exposed to different chlorpheniramine concentrations. To assess cell growth, cells are cleaned, separated, and counted using a Coulter counter.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C20H23CLN2O4
|
|
|---|---|---|
| Molecular Weight |
390.86
|
|
| Exact Mass |
390.13
|
|
| Elemental Analysis |
C, 61.46; H, 5.93; Cl, 9.07; N, 7.17; O, 16.37
|
|
| CAS # |
113-92-8
|
|
| Related CAS # |
Chlorpheniramine; 132-22-9; Chlorpheniramine-d4 maleate; 2747915-71-3
|
|
| Appearance |
White crystalline solid
|
|
| SMILES |
CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O
|
|
| InChi Key |
DBAKFASWICGISY-BTJKTKAUSA-N
|
|
| InChi Code |
InChI=1S/C16H19ClN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
|
|
| Chemical Name |
(Z)-but-2-enedioic acid;3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: Saline: 20 mg/mL Solubility in Formulation 5: 120 mg/mL (307.02 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5585 mL | 12.7923 mL | 25.5846 mL | |
| 5 mM | 0.5117 mL | 2.5585 mL | 5.1169 mL | |
| 10 mM | 0.2558 mL | 1.2792 mL | 2.5585 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05520944 | Active Recruiting |
Drug: ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray |
COVID-19 COVID-19 Pandemic SARS CoV 2 Infection |
Dr. Ferrer BioPharma | August 26, 2021 | N/A |
| NCT04688736 | Recruiting | Drug: Placebo Drug: Chlorpheniramine |
Allergic Transfusion Reaction | Institute of Hematology & Blood Diseases Hospital, China |
January 1, 2021 | Phase 2 |
| NCT05858216 | Not yet recruiting | Drug: Chlor-Trimeton | Voice Disorder Due to Iatrogenic Factor |
Auburn University | May 15, 2023 | Early Phase 1 |
| NCT00837837 | Completed | Drug: Chlorpheniramine | Allergic Reactions | Wyeth is now a wholly owned subsidiary of Pfizer |
December 21, 2008 | Phase 1 |
| NCT02246166 | Completed | Drug: Test tablet Other: Placebo |
Common Cold | GlaxoSmithKline | January 2015 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA